From COVID-19 to encephalitic alphaviruses, School of Pharmacy Associate Professor Jennifer Golden and collaborators are developing new antiviral treatments.

From COVID-19 to encephalitic alphaviruses, School of Pharmacy Associate Professor Jennifer Golden and collaborators are developing new antiviral treatments.
The School of Pharmacy makes a breakthrough in creating new small molecules that penetrate into the brain where the equine encephalitis viruses reside and interfere with viral replication to stop EEV. The research is funded by a new, five-year $21 million award from the National Institutes of Health (NIH).